Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive® Robotic Navigation System
29 April 2016 - 11:00PM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, today
announced that the U.S. Patent and Trademark Office issued U.S.
Patent No. 9,314,222 titled, “Operation of a Remote Medical
Navigation System Using Ultrasound Image.” The patent protects the
current Spotlight feature of the Company’s Vmotion suite of
automations, which enables automatic orientation of a magnetically
compatible Intracardiac Echocardiography (ICE), or ultrasound,
catheter to track a localized ablation catheter in conjunction with
the Vdrive® system with V-Sono™ ICE catheter manipulator.
“This patent represents another important step in the expansion
of our proprietary technology for enhanced treatment of arrhythmias
and coronary disease,” said William C. Mills, Stereotaxis Chief
Executive Officer. “The Vmotion Spotlight feature stands to
positively impact both physicians and patients by improving the
clinical utility of ultrasound imaging and further reducing
reliance on fluoroscopy during ablation therapy delivery.”
Cleared by the FDA in June 2015, the Vmotion automation
features, in combination with the V-Sono™ ICE catheter manipulator,
are designed to enhance the physician’s ability to visualize, in
real-time, the tip-to-tissue contact of the ablation catheter
throughout a procedure using the Niobe® ES remote magnetic
navigation system. As the ablation catheter moves within the heart,
the Spotlight feature automatically adjusts the ICE catheter in
order to keep the ablation catheter tip in its field of view.
Spotlight is one of three automation features of Vmotion, which
enable single-operator workflow by eliminating the need for manual
ICE manipulation within the radiation field, reducing radiation
exposure to the clinical team. Vmotion can also improve procedure
outcomes through more exact ultrasound imaging.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® ES remote
magnetic navigation system, the Odyssey® portfolio of lab
optimization, networking and patient information management
systems, and the Vdrive® robotic navigation system and
consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
STXS Company Contact:
Martin Stammer
Chief Financial Officer
314-678-6155
STXS Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com